Lancashire and South Cumbria
Formulary
4 Central nervous system
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents:
mlcsu.lscformulary@nhs.net
.
For more information about the formulary development process, please see:
https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
04-09-01 Catachol-O-methyltransferase inhibitors
Entacapone
Comtess
®
Formulary
Opicapone
Ongentys
®
Formulary
Capsules 50mg
Tolcapone
Tasmar
®
Formulary
Tablets 100mg
Third Line
Links
BNF: Parkinson’s disease
How do you convert from co-beneldopa (Madopar®) prolonged-release capsules to dispersible tablets?
LSCMMG: Shared care guideline
LSCMMG: The Management of Restless Legs Syndrome in Adults in Primary Care
MHRA Drug Safety Update April 2016: Apomorphine with domperidone: minimising risk of cardiac side effects
MHRA: Apomorphine with domperidone: minimising risk of cardiac side effects
NICE NG71: Parkinson’s disease in adults
NICE TA934: Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms
NICE TA934:Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms
Shared Care Guideline - Apomorphine
Key
Full Site